Welcome to our dedicated page for EVOGENE LTD. news (Ticker: EVGN), a resource for investors and traders seeking the latest updates and insights on EVOGENE LTD. stock.
Evogene Ltd. (Nasdaq: EVGN, TASE: EVGN) is a leading computational biology company leveraging big data and artificial intelligence to revolutionize the development of life-science-based products. The company, headquartered in Rehovot, Israel, employs cutting-edge technologies to increase the probability of success while reducing development time and cost across multiple market segments including human health, agriculture, and industrial applications. Evogene has established three unique tech-engines - MicroBoost AI, ChemPass AI, and GeneRator AI - each focused on products based on microbes, small molecules, and genetic elements respectively.
The company operates through several subsidiaries that utilize these tech-engines:
- Biomica Ltd.: Develops microbiome-based therapeutics for diseases such as antibiotic-resistant bacteria, cancer, and gastrointestinal disorders.
- Lavie Bio Ltd.: Focuses on microbiome-based ag-biologicals to enhance crop yield and sustainability.
- AgPlenus Ltd.: Innovates in sustainable crop protection products.
- Canonic Ltd.: Develops medical cannabis products.
- Casterra Ag Ltd.: Produces high-yield castor seeds for biofuels and other industrial uses.
Evogene's recent achievements include securing new seed production agreements for Casterra, advancing clinical trials for Biomica's immuno-oncology candidate BMC128, and extending validation trials for Lavie Bio's biofungicides in collaboration with Bayer AG. Evogene has been proactive in addressing its Nasdaq listing compliance and continues to prioritize innovation through strategic partnerships and collaborative ventures. For more information, please visit www.evogene.com.
Rhea-AI Summary
Evogene and The Kitchen FoodTech Hub have established Finally Foods , an AI-driven company focusing on molecular farming for sustainable alternative protein sources. Finally Foods aims to revolutionize the food industry using Evogene's GeneRator AI technology. The global alternative proteins market is growing rapidly, with Finally Foods well-positioned to capitalize on this trend.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.56%
Tags
-
Rhea-AI Summary
Evogene (EVGN) filed its Annual Report on Form 20-F for the fiscal year ended December 31, 2023. The report can be accessed on the Company's investor relations website and the SEC's website. Security holders can request a hard copy for free.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.35%
Tags
-
Rhea-AI Summary
Evogene received a letter from Nasdaq indicating non-compliance with the minimum bid price requirement. The company has 180 days to regain compliance by maintaining a closing bid price of at least $1.00 for ten consecutive business days.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
Rhea-AI Summary
Lavie Bio , a subsidiary of Evogene , extends joint validation trials with Bayer AG for its biofungicides after successful initial testing. The trials aim to address devastating diseases affecting fruits and vegetables globally, showcasing promising results. The collaboration highlights the potential of biofungicides in sustainable agriculture and signifies a significant step in open innovation strategies.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.23%
Tags
-
Rhea-AI Summary
Lavie Bio Ltd., a subsidiary of Evogene Ltd., partners with Ceres Global Ag Corp. to integrate its bio-inoculant, YalosTM, into regenerative agriculture initiatives in the USA and Canada. Ceres aims to enhance sustainability and productivity in the agricultural industry through this collaboration.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.1%
Tags
-
Rhea-AI Summary
Evogene Ltd. announces financial results for Q4 and full-year 2023, showcasing revenue growth and successful collaborations. The company's AI tech-engines drive partnerships with industry leaders, leading to revenue streams and expanding sales. Evogene's subsidiaries achieve significant milestones in various sectors, reflecting a positive outlook for 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.23%
Tags
Rhea-AI Summary
AgPlenus Ltd., a subsidiary of Evogene Ltd., achieves a milestone in collaboration with Corteva Agriscience for novel herbicides. The successful identification of a new family of molecules with herbicidal effect through a novel Mode of Action marks a significant development in addressing weed resistance challenges in the agricultural industry.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.17%
Tags
-
Rhea-AI Summary
Casterra Ag Ltd., a subsidiary of Evogen Ltd., signed strategic agreements with seed producers in Brazil and Africa to enhance castor seed production, adding 400 tons in 2024. The agreements aim to establish long-term production infrastructure and lower production risks by expanding geographies of seed producers.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.03%
Tags
-
Rhea-AI Summary
Lavie Bio Ltd., a subsidiary of Evogene Ltd., secures $2.5 million as the second-half advance payment under the licensing agreement with Corteva, completing a total $5 million advance payment. The agreement grants Corteva exclusive rights to develop and commercialize bio-fungicide products targeting fruit rots and powdery mildew. Lavie Bio will receive future milestone payments and royalties from Corteva's sales.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.07%
Tags
Rhea-AI Summary
Evogene Ltd. (EVGN) to release financial results for Q3 2023 on March 7th, 2024. Conference call scheduled for 9:00 AM ET. Company aims to revolutionize life-science product discovery and development. Replay and webcast details provided for investor access.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.12%
Tags
FAQ
What is the current stock price of EVOGENE LTD. (EVGN)?
The current stock price of EVOGENE LTD. (EVGN) is $1.68 as of November 18, 2024.
What is the market cap of EVOGENE LTD. (EVGN)?
The market cap of EVOGENE LTD. (EVGN) is approximately 9.3M.
What does Evogene Ltd. do?
Evogene Ltd. is a computational biology company that uses AI and big data to develop life-science-based products in human health, agriculture, and industrial applications.
Where is Evogene Ltd. headquartered?
Evogene Ltd. is headquartered in Rehovot, Israel.
What are Evogene's main technology platforms?
Evogene has three main tech-engines: MicroBoost AI for microbes, ChemPass AI for small molecules, and GeneRator AI for genetic elements.
Who are some of Evogene's subsidiaries?
Evogene's subsidiaries include Biomica Ltd., Lavie Bio Ltd., AgPlenus Ltd., Canonic Ltd., and Casterra Ag Ltd.
What is the focus of Biomica Ltd.?
Biomica Ltd. focuses on developing microbiome-based therapeutics for diseases such as antibiotic-resistant bacteria, cancer, and gastrointestinal disorders.
What recent partnerships has Evogene engaged in?
Evogene recently extended validation trials for Lavie Bio's biofungicides with Bayer AG, and secured new seed production agreements for Casterra.
How is Evogene addressing its Nasdaq listing compliance?
Evogene is actively working to regain compliance with Nasdaq's listing requirements and considers various options, including reverse share splits, to maintain its listing.
What are some recent achievements of Evogene Ltd.?
Evogene has advanced clinical trials for Biomica's BMC128, secured new seed production agreements for Casterra, and extended biofungicide validation trials with Bayer AG.
Where can I find more information about Evogene Ltd.?
More information about Evogene Ltd. can be found on their official website at www.evogene.com.
What market segments does Evogene target?
Evogene targets human health, agriculture, and industrial applications through its computational biology platforms and subsidiaries.
EVOGENE LTD.